UY38562A - Compuestos y métodos para reducir la expresión de app - Google Patents
Compuestos y métodos para reducir la expresión de appInfo
- Publication number
- UY38562A UY38562A UY0001038562A UY38562A UY38562A UY 38562 A UY38562 A UY 38562A UY 0001038562 A UY0001038562 A UY 0001038562A UY 38562 A UY38562 A UY 38562A UY 38562 A UY38562 A UY 38562A
- Authority
- UY
- Uruguay
- Prior art keywords
- methods
- compounds
- reduce
- animal
- cell
- Prior art date
Links
- 150000001875 compounds Chemical class 0.000 title abstract 3
- 208000024891 symptom Diseases 0.000 abstract 3
- 206010002942 Apathy Diseases 0.000 abstract 2
- 239000008194 pharmaceutical composition Substances 0.000 abstract 2
- 208000037259 Amyloid Plaque Diseases 0.000 abstract 1
- 208000028698 Cognitive impairment Diseases 0.000 abstract 1
- 206010010904 Convulsion Diseases 0.000 abstract 1
- 206010012289 Dementia Diseases 0.000 abstract 1
- 206010017577 Gait disturbance Diseases 0.000 abstract 1
- 230000002159 abnormal effect Effects 0.000 abstract 1
- 230000003542 behavioural effect Effects 0.000 abstract 1
- 208000010877 cognitive disease Diseases 0.000 abstract 1
- 230000000694 effects Effects 0.000 abstract 1
- 230000001771 impaired effect Effects 0.000 abstract 1
- 230000004770 neurodegeneration Effects 0.000 abstract 1
- 208000015122 neurodegenerative disease Diseases 0.000 abstract 1
- 230000000750 progressive effect Effects 0.000 abstract 1
- 102000004169 proteins and genes Human genes 0.000 abstract 1
- 108090000623 proteins and genes Proteins 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
- C12N15/1138—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against receptors or cell surface proteins
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/10—Type of nucleic acid
- C12N2310/14—Type of nucleic acid interfering nucleic acids [NA]
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/31—Chemical structure of the backbone
- C12N2310/315—Phosphorothioates
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/32—Chemical structure of the sugar
- C12N2310/321—2'-O-R Modification
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/32—Chemical structure of the sugar
- C12N2310/322—2'-R Modification
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/32—Chemical structure of the sugar
- C12N2310/323—Chemical structure of the sugar modified ring structure
- C12N2310/3231—Chemical structure of the sugar modified ring structure having an additional ring, e.g. LNA, ENA
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/33—Chemical structure of the base
- C12N2310/334—Modified C
- C12N2310/3341—5-Methylcytosine
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/34—Spatial arrangement of the modifications
- C12N2310/341—Gapmers, i.e. of the type ===---===
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/34—Spatial arrangement of the modifications
- C12N2310/343—Spatial arrangement of the modifications having patterns, e.g. ==--==--==--
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/34—Spatial arrangement of the modifications
- C12N2310/345—Spatial arrangement of the modifications having at least two different backbone modifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/34—Spatial arrangement of the modifications
- C12N2310/346—Spatial arrangement of the modifications having a combination of backbone and sugar modifications
Landscapes
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Life Sciences & Earth Sciences (AREA)
- Genetics & Genomics (AREA)
- Biomedical Technology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Organic Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Biotechnology (AREA)
- General Engineering & Computer Science (AREA)
- Zoology (AREA)
- Molecular Biology (AREA)
- Wood Science & Technology (AREA)
- General Health & Medical Sciences (AREA)
- Biochemistry (AREA)
- Plant Pathology (AREA)
- Biophysics (AREA)
- Physics & Mathematics (AREA)
- Microbiology (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Psychiatry (AREA)
- Hospice & Palliative Care (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201962798353P | 2019-01-29 | 2019-01-29 | |
| US201962841169P | 2019-04-30 | 2019-04-30 | |
| US201962915764P | 2019-10-16 | 2019-10-16 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| UY38562A true UY38562A (es) | 2020-08-31 |
Family
ID=71840111
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| UY0001038562A UY38562A (es) | 2019-01-29 | 2020-01-29 | Compuestos y métodos para reducir la expresión de app |
Country Status (6)
| Country | Link |
|---|---|
| US (1) | US20220380773A1 (cg-RX-API-DMAC7.html) |
| EP (1) | EP3918073A4 (cg-RX-API-DMAC7.html) |
| JP (2) | JP7557469B2 (cg-RX-API-DMAC7.html) |
| TW (1) | TW202043472A (cg-RX-API-DMAC7.html) |
| UY (1) | UY38562A (cg-RX-API-DMAC7.html) |
| WO (1) | WO2020160163A1 (cg-RX-API-DMAC7.html) |
Families Citing this family (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| MY203356A (en) | 2018-01-12 | 2024-06-25 | Bristol Myers Squibb Co | Antisense oligonucleotides targeting alpha-synuclein and uses thereof |
| WO2019140236A1 (en) | 2018-01-12 | 2019-07-18 | Bristol-Myers Squibb Company | Antisense oligonucleotides targeting alpha-synuclein and uses thereof |
| WO2019169243A1 (en) | 2018-03-02 | 2019-09-06 | Ionis Pharmaceuticals, Inc. | Compounds and methods for the modulation of amyloid-beta precursor protein |
| AU2019405783B2 (en) * | 2018-12-19 | 2026-03-26 | Alnylam Pharmaceuticals, Inc. | Amyloid precursor protein (APP) RNAi agent compositions and methods of use thereof |
| JP7725370B2 (ja) * | 2019-04-03 | 2025-08-19 | ブリストル-マイヤーズ スクイブ カンパニー | Angptl2アンチセンスオリゴヌクレオチドおよびその使用 |
| KR20220062517A (ko) | 2019-08-15 | 2022-05-17 | 아이오니스 파마수티컬즈, 인코포레이티드 | 결합 변형된 올리고머 화합물 및 이의 용도 |
| MX2023001222A (es) | 2020-07-28 | 2023-04-26 | Ionis Pharmaceuticals Inc | Compuestos y metodos para reducir la expresion de app. |
| WO2022165172A1 (en) * | 2021-01-29 | 2022-08-04 | Alnylam Pharmaceuticals, Inc. | Irna compositions and methods for silencing amyloid precursor protein (app) |
| EP4416284A1 (en) * | 2021-10-15 | 2024-08-21 | Alnylam Pharmaceuticals, Inc. | Extra-hepatic delivery irna compositions and methods of use thereof |
| WO2025045195A1 (zh) * | 2023-08-31 | 2025-03-06 | 上海拓界生物医药科技有限公司 | 靶向APP的RNAi剂及其医药用途 |
| WO2025228429A1 (zh) * | 2024-04-30 | 2025-11-06 | 北京安龙生物医药有限公司 | 靶向淀粉样前体蛋白基因的寡核苷酸及其用途 |
| WO2025261396A1 (zh) * | 2024-06-18 | 2025-12-26 | 艾码生物科技(南京)有限公司 | 靶向app的rna干扰方法、核酸及其应用 |
| WO2026092658A2 (en) * | 2024-10-31 | 2026-05-07 | Sanegene Bio Usa Inc. | Small interfering rna targeting amyloid beta precursor protein (app) and uses thereof |
Family Cites Families (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPH06511387A (ja) * | 1991-12-24 | 1994-12-22 | アイシス・ファーマシューティカルス・インコーポレーテッド | β−アミロイド調節のための組成物および方法 |
| US20030232435A1 (en) * | 2002-06-14 | 2003-12-18 | Isis Pharmaceuticals Inc. | Antisense modulation of amyloid beta protein precursor expression |
| CA2528963A1 (en) * | 2003-06-27 | 2005-01-13 | Sirna Therapeutics, Inc. | Rna interference mediated treatment of alzheimer's disease using short interfering nucleic acid (sina) |
| GB0324854D0 (en) * | 2003-10-24 | 2003-11-26 | Expresson Biosystems Ltd | App/ena antisense |
| US20110166197A1 (en) | 2008-02-19 | 2011-07-07 | Edunn Biotechnology, Inc. | Antisense Modulation Of Amyloid Beta Protein Expression |
| US20100190807A1 (en) * | 2008-08-26 | 2010-07-29 | Senex Biotechnology, Inc. | CDKI Pathway inhibitors and uses thereof to regulate expression to TAU protein |
| WO2011130742A2 (en) * | 2010-04-16 | 2011-10-20 | Wisconsin Alumni Research Foundation | Diagnostic evaluation of antibody responses to commonly recognized prostate cancer-associated antigens |
| KR20160027968A (ko) | 2013-06-07 | 2016-03-10 | 라나 테라퓨틱스, 인크. | Foxp3 발현을 조절하기 위한 조성물 및 방법 |
| JP2016531570A (ja) | 2013-08-16 | 2016-10-13 | ラナ セラピューティクス インコーポレイテッド | ユークロマチン領域を標的とするオリゴヌクレオチド |
| MY192689A (en) | 2013-10-11 | 2022-09-01 | Ionis Pharmaceuticals Inc | Compositions for modulating c9orf72 expression |
| US9926556B2 (en) | 2014-04-28 | 2018-03-27 | Ionis Pharmaceuticals, Inc. | Linkage modified oligomeric compounds |
| WO2019169243A1 (en) * | 2018-03-02 | 2019-09-06 | Ionis Pharmaceuticals, Inc. | Compounds and methods for the modulation of amyloid-beta precursor protein |
-
2020
- 2020-01-29 JP JP2021544144A patent/JP7557469B2/ja active Active
- 2020-01-29 WO PCT/US2020/015701 patent/WO2020160163A1/en not_active Ceased
- 2020-01-29 US US17/424,672 patent/US20220380773A1/en active Pending
- 2020-01-29 EP EP20749114.3A patent/EP3918073A4/en active Pending
- 2020-01-29 UY UY0001038562A patent/UY38562A/es not_active Application Discontinuation
- 2020-01-30 TW TW109102899A patent/TW202043472A/zh unknown
-
2024
- 2024-09-13 JP JP2024158813A patent/JP2025000693A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| US20220380773A1 (en) | 2022-12-01 |
| JP7557469B2 (ja) | 2024-09-27 |
| JP2025000693A (ja) | 2025-01-07 |
| WO2020160163A1 (en) | 2020-08-06 |
| TW202043472A (zh) | 2020-12-01 |
| EP3918073A4 (en) | 2023-11-22 |
| EP3918073A1 (en) | 2021-12-08 |
| JP2022518929A (ja) | 2022-03-17 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| UY39344A (es) | Compuestos y métodos para reducir la expresión de app | |
| Opresko et al. | Telomere-associated aging disorders | |
| CL2020003309A1 (es) | Compuestos y métodos para la reducción de la expresión de lrrk2 | |
| Taddei et al. | Management of psychosis in Parkinson’s disease: emphasizing clinical subtypes and pathophysiological mechanisms of the condition | |
| Sierksma et al. | Major depression, cognitive dysfunction and Alzheimer's disease: is there a link? | |
| Campos et al. | Treatment of Cognitive Deficits in Alzheimer's disease: A psychopharmacological review | |
| CO2020004762A2 (es) | Compuestos y métodos para la reducción de la expresión de snca | |
| EA201491534A1 (ru) | Ингибиторы бета-секретазы | |
| Ruffolo et al. | A novel action of lacosamide on GABAA currents sets the ground for a synergic interaction with levetiracetam in treatment of epilepsy | |
| CO6731117A2 (es) | Metodos para diagnosticar y tratar desórdenes relacionados con la longitud axial del ojo | |
| DOP2018000150A (es) | Compuestos de diamina-arilsulfonamida sustituidos con hidroxialquilamina e hidroxicicloalquilamina con actividad selectiva en canales de sodio activados por voltaje | |
| JOP20200283A1 (ar) | مركبات وطرق لتقليل التعبير الوراثي عن atxn3 | |
| BR112018067946A8 (pt) | Formulações tópicas contendo ciclosporina e usos das mesmas | |
| Orzechowska et al. | Influence of pharmacotherapy on cognitive functions in depression: a review of the literature | |
| MX388366B (es) | Composiciones para tratar enfermedades neurodegenerativas. | |
| Kubota et al. | Emotional stress evoked by classical fear conditioning induces yawning behavior in rats | |
| Buoli et al. | May non-antipsychotic drugs improve cognition of schizophrenia patients? | |
| AR119686A1 (es) | Compuestos y métodos para reducir la expresión de app | |
| CS Costa | The glutamatergic hypothesis for Down syndrome: the potential use of N-methyl-D-aspartate receptor antagonists to enhance cognition and decelerate neurodegeneration | |
| WO2024173762A3 (en) | Compounds and methods for reducing app expression | |
| AR123066A1 (es) | Compuestos y métodos para reducir la expresión de app | |
| UY34281A (es) | "1,4-diazabiciclo[3.2.2]nonanos como ligandos de receptores nicotínicos neuronales de acetilcolina | |
| Lillig | Development of a New CERAD Total Score in Individuals with Parkinson's Disease: Evidence from the LANDSCAPE Study | |
| Da Cunha et al. | A rat model of the cognitive impairments in PARKINSON¿ S disease | |
| Xua et al. | Use of Antipsychotics in Patients with Alzheimer’s |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| 109 | Application deemed to be withdrawn |
Effective date: 20241111 |